Literature DB >> 25400741

Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway.

Sainan Zhang1, Naibin Yang1, Shunlan Ni1, Wenyuan Li2, Lanman Xu1, Peihong Dong1, Mingqin Lu1.   

Abstract

Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to investigate the protecting mechanisms of endotoxin tolerance in acute liver failure induced by D-galactosamine (D-GalN)/LPS and possible role of toll-like receptors 4 (TLR4) signaling pathway in this phenomenon. Acute liver failure was induced by Injection of D-GalN/LPS. To mimic endotoxin tolerance, male Sprague-Dawley rats were treated with low dose of LPS (0.1 mg/kg once a day intraperitoneally for consecutive five days) before subsequent injection of D-GalN/LPS. Rat survival was determined by survival rate. Liver injury was confirmed by serum biochemical and liver histopathological examination. Inflammatory cytokines were determined by ELISA and nuclear factor-kappa B (NF-κB) (P65), toll-like receptors 4 (TLR4) and Interleukin-1 receptor-associated kinase-1 (IRAK-1) were measured by reverse transcriptase polymerase chain reaction and western blot respectively. Pretreatment of LPS significantly improved rat survival. Moreover, rats pretreated with LPS exhibited lower serum enzyme (ALT, AST and TBiL) level, lower production of inflammatory cytokines and more minor liver histopathological damage than rats without pretreatment of LPS. LPS pretreatment suppressed production of TLR4 and IRAK-1. LPS pretreatment also inhibited activation of hepatic NF-κB. These results indicated that endotoxin tolerance contributed to liver protection against D-GalN/LPS induced acute liver failure through down-regulation of TLR4 and NF-κB pathway.

Entities:  

Keywords:  D-GalN/LPS; Endotoxin tolerance; NF-κB; TLR4; liver failure

Mesh:

Substances:

Year:  2014        PMID: 25400741      PMCID: PMC4230075     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

1.  Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages.

Authors:  M Lin; R A Rippe; O Niemelä; G Brittenham; H Tsukamoto
Journal:  Am J Physiol       Date:  1997-06

Review 2.  Apoptosis in liver disease.

Authors:  P R Galle
Journal:  J Hepatol       Date:  1997-08       Impact factor: 25.083

3.  Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand.

Authors:  M D Josephs; F R Bahjat; K Fukuzuka; R Ksontini; C C Solorzano; C K Edwards; C L Tannahill; S L MacKay; E M Copeland; L L Moldawer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-05       Impact factor: 3.619

4.  Protective effect of melittin on inflammation and apoptosis in acute liver failure.

Authors:  Ji-Hyun Park; Kyung-Hyun Kim; Woo-Ram Lee; Sang-Mi Han; Kwan-Kyu Park
Journal:  Apoptosis       Date:  2012-01       Impact factor: 4.677

5.  Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis.

Authors:  T Nishikage; S Seki; S Toyabe; T Abo; Y Kagata; T Iwai; H Hiraide
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

6.  LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock.

Authors:  A Mignon; N Rouquet; M Fabre; S Martin; J C Pagès; J F Dhainaut; A Kahn; P Briand; V Joulin
Journal:  Am J Respir Crit Care Med       Date:  1999-04       Impact factor: 21.405

7.  Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK-1 activation in the NF-κB and MAPK pathways.

Authors:  Eun-Ha Joh; Dong-Hyun Kim
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

8.  Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model.

Authors:  Ichiro Ogushi; Yuji Iimuro; Ekihiro Seki; Gakuhei Son; Tadamichi Hirano; Toshikazu Hada; Hiroko Tsutsui; Kenji Nakanishi; Ryuichi Morishita; Yasufumi Kaneda; Jiro Fujimoto
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

10.  Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1.

Authors:  Valerie Albrecht; Thomas P J Hofer; Brian Foxwell; Marion Frankenberger; Loems Ziegler-Heitbrock
Journal:  BMC Immunol       Date:  2008-11-24       Impact factor: 3.615

View more
  15 in total

1.  Endotoxin tolerance alleviates experimental acute liver failure via inhibition of high mobility group box 1.

Authors:  Nai-Bin Yang; Shun-Lan Ni; Shan-Shan Li; Sai-Nan Zhang; Dan-Ping Hu; Ming-Qin Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Improved prescription of taohechengqi-tang alleviates D-galactosamine acute liver failure in rats.

Authors:  Yang Zhang; Jian-Xing Luo; Xiao-Yu Hu; Fang Yang; Sen Zhong; Wu Lin
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

3.  Hepatoprotective activity of Lepidium sativum seeds against D-galactosamine/lipopolysaccharide induced hepatotoxicity in animal model.

Authors:  Mohammad Raish; Ajaz Ahmad; Khalid M Alkharfy; Syed Rizwan Ahamad; Kazi Mohsin; Fahad I Al-Jenoobi; Abdullah M Al-Mohizea; Mushtaq Ahmad Ansari
Journal:  BMC Complement Altern Med       Date:  2016-12-03       Impact factor: 3.659

4.  Herbal Compound "Jiedu Huayu" Reduces Liver Injury in Rats via Regulation of IL-2, TLR4, and PCNA Expression Levels.

Authors:  Minggang Wang; Qinglan Shi; Rongzhen Zhang; Hua Qiu; Dewen Mao; Fuli Long
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-19       Impact factor: 2.629

5.  Transcriptome Analysis of Porcine PBMCs Reveals the Immune Cascade Response and Gene Ontology Terms Related to Cell Death and Fibrosis in the Progression of Liver Failure.

Authors:  YiMin Zhang; Li Shao; Ning Zhou; JianZhou Li; Yu Chen; Juan Lu; Jie Wang; ErMei Chen; ZhongYang Xie; LanJuan Li
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-12

6.  Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3.

Authors:  Yangliu Xia; Ping Wang; Nana Yan; Frank J Gonzalez; Tingting Yan
Journal:  Cell Death Dis       Date:  2021-02-11       Impact factor: 8.469

7.  Splenic CD11c(low)CD45RB(high) dendritic cells derived from endotoxin-tolerant mice attenuate experimental acute liver failure.

Authors:  Sai-Nan Zhang; Nai-Bin Yang; Shun-Lan Ni; Jin-Zhong Dong; Chun-Wei Shi; Shan-Shan Li; Sheng-Guo Zhang; Xin-Yue Tang; Ming-Qin Lu
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

8.  Protective effect of ultrasonication-processed ginseng berry extract on the D-galactosamine/lipopolysaccharide-induced liver injury model in rats.

Authors:  Yoonjin Nam; Jinhyung Bae; Ji Hoon Jeong; Sung Kwon Ko; Uy Dong Sohn
Journal:  J Ginseng Res       Date:  2017-07-25       Impact factor: 6.060

9.  Trained immunity modulates inflammation-induced fibrosis.

Authors:  Mohamed Jeljeli; Luiza Gama Coelho Riccio; Ludivine Doridot; Charlotte Chêne; Carole Nicco; Sandrine Chouzenoux; Quentin Deletang; Yannick Allanore; Niloufar Kavian; Frédéric Batteux
Journal:  Nat Commun       Date:  2019-12-11       Impact factor: 14.919

Review 10.  The Central Role and Possible Mechanisms of Bacterial DNAs in Sepsis Development.

Authors:  Zhenxing Cheng; Simon T Abrams; James Austin; Julien Toh; Susan Siyu Wang; Zhi Wang; Qian Yu; Weiping Yu; Cheng Hock Toh; Guozheng Wang
Journal:  Mediators Inflamm       Date:  2020-08-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.